TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14728759

Group type: EXPERIMENTAL
Intervention: Telerehabilitation system
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual face-to-face method (Control)
Number of subjects: 21
Study: 11590492

Group type: EXPERIMENTAL
Intervention: Treatment 1 (didanosine 400 mg/day, stavudine 60/80 mg/day, and HU 500 mg/day)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Treatment 3 (didanosine, indinavir, and HU 500-1,000 mg/day)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Treatment 2 (two nucleosides plus a protease inhibitor)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Treatment 1
Number of subjects: 284

Group type: COMPARATOR
Intervention: Treatment 2
Number of subjects: 284
Study: 8774217

Group type: EXPERIMENTAL
Intervention: Guar wheatflake meal (6.3 g guar gum)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control meal (0 g guar gum)
Number of subjects: 10
Study: 1534642

Group type: EXPERIMENTAL
Intervention: Sustained-release nicardipine
Number of subjects: 28
Study: 6377152

Group type: EXPERIMENTAL
Intervention: Glucose tolerance test
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Glucose polymer tolerance test
Number of subjects: 46
Study: 31449090

Group type: EXPERIMENTAL
Intervention: Enhanced testing, linkage to care, and ARV treatment in 15 intervention villages.
Number of subjects: 100000
Study: 29310703

Group type: EXPERIMENTAL
Intervention: Floseal® (Baxter, USA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional nasal packing
Number of subjects: 0
Study: 26632428

Group type: EXPERIMENTAL
Intervention: 1.5 mg melatonin (Melaxen(TM)) daily at 22:30 h for two weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 97
Study: 24958736

Group type: EXPERIMENTAL
Intervention: UFT/LV (UFT 300 mg m(‐2) day(‐1), LV 75 mg/day on days 1-28 every 5 weeks)
Number of subjects: 1101

Group type: COMPARATOR
Intervention: 5‐FU/l‐LV (5‐FU 500 mg/m(2), l‐LV 250 mg/m(2) on days 1, 8, 15, 22, 29, 36 every 8 weeks)
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 1101

Group type: COMPARATOR
Intervention: 5‐FU/l‐LV
Number of subjects: 1101
Study: 22429357

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI with desflurane
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI with sevoflurane
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI for preventing cough during emergence from desflurane anaesthesia
Number of subjects: 48
Study: 19769614

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 17825800

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75-300 mg/day)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Fluoxetine (20-60 mg/day)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (continuation phase)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Fluoxetine (continuation phase)
Number of subjects: 821
Study: 16362597

Group type: EXPERIMENTAL
Intervention: Terazosin 5 mg daily for one month
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo for one month
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Terazosin 10 mg after one month for group 2 and those with improvement or ineffectiveness from 5 mg
Number of subjects: 90
Study: 12133195

Group type: EXPERIMENTAL
Intervention: New evidence-based antenatal care model
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Standard antenatal care model
Number of subjects: 1600
Study: 10080319

Group type: EXPERIMENTAL
Intervention: Implant-supported mandibular overdenture on a transmandibular implant (TMI)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Implant-tissue-supported mandibular overdenture on two IMZ implants (IMZ)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional complete dentures (CD)
Number of subjects: 3
Study: 7562122

Group type: EXPERIMENTAL
Intervention: One-month intensive training centered on psychosocial skills
Number of subjects: 26
Study: 1539851

Group type: EXPERIMENTAL
Intervention: Heparin 200 U/kg and additional heparin as needed to maintain ACT > 400 s (group A, n = 30)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Heparin 400 U/kg and additional heparin as needed to maintain whole blood heparin concentration > 4.0 U/ml (group H, n = 33)
Number of subjects: 63
Study: 3895948

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 74
Study: 30094732

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 825

Group type: COMPARATOR
Intervention: Granisetron
Number of subjects: 825
Study: 29545471

Group type: EXPERIMENTAL
Intervention: HIV/AIDS
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: AIDS death
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: TB/HIV
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: TB/HIV death
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: LTBI/HIV
Number of subjects: 239
Study: 27098551

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (IV-D)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Oral dexamethasone (PO-D)
Number of subjects: 288
Study: 25140086

Group type: EXPERIMENTAL
Intervention: Neuromobilization combined with routine physiotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 20
Study: 22560728

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 109
Study: 20218793

Group type: COMPARATOR
Intervention: Usual starting dose of SSRIs (10 mg escitalopram; 20 mg fluoxetine, paroxetine, citalopram; 50 mg sertraline and fluvoxamine)
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: Higher starting doses of SSRIs
Number of subjects: 2340

Group type: COMPARATOR
Intervention: Usual starting dose of SSRIs
Number of subjects: 2340
Study: 18767581

Group type: EXPERIMENTAL
Intervention: Turtle probing the cave needling method (acupuncture therapy), treated once a day for two weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Motilium (10 mg oral administration, thrice daily, 30 minutes before meals, for two weeks).
Number of subjects: 60
Study: 15982149

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (present-centered therapy; PCT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 74
Study: 12066947

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9737828

Group type: EXPERIMENTAL
Intervention: 5 mg lubeluzole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg lubeluzole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg lubeluzole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All doses of lubeluzole (5, 10, 15 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All doses of lubeluzole
Number of subjects: 12
Study: 7918310

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid ethyl esters (3 g/d) administered to healthy volunteers for 18 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid ethyl esters (3 g/d) administered to hypertriglyceridemic patients for 24 weeks
Number of subjects: 30
Study: 3042399

Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Gallium-67 myocardial scintigraphy
Number of subjects: 91
Study: 30312163

Group type: EXPERIMENTAL
Intervention: Complementary Spiritist Therapy (3 days, 10 mins per day/session) alongside conventional treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 41
Study: 27616732

Group type: EXPERIMENTAL
Intervention: 7% maltodextrin solution (CHO)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 14% maltodextrin solution (CHO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Taste-matched placebo (PLA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RPE
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GI comfort
Number of subjects: 11
Study: 25795276

Group type: EXPERIMENTAL
Intervention: Predictive language input (highly predictable words)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive arrow cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vocabulary size and verbal fluency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control object (unrelated object)
Number of subjects: 0
Study: 24103519

Group type: EXPERIMENTAL
Intervention: Oleaginous extract of kale (50 mL providing 10 mg lutein and 3 mg zeaxanthin per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Refined rapeseed oil (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Kale group
Number of subjects: 20
Study: 21118623

Group type: EXPERIMENTAL
Intervention: Infloran(®) stored at 4°C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infloran(®) stored at room temperature (28-32°C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18651320

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16556674

Group type: EXPERIMENTAL
Intervention: Echogenic catheter
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 193
Study: 14519051

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Beta-blockers and diuretics
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Diuretics and calcium-channel blockers
Number of subjects: 281
Study: 10730357

Group type: EXPERIMENTAL
Intervention: Training group with elastic lumbar belts
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Training group without elastic lumbar belts
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Training group with elastic lumbar belts (low back pain patients)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Training group without elastic lumbar belts (low back pain patients)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Training group with elastic lumbar belts (healthy backs)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (healthy backs)
Number of subjects: 97
Study: 9172188

Group type: EXPERIMENTAL
Intervention: telic-low arousal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: paratelic-low arousal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: telic-high arousal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: paratelic-high arousal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: combined high (telic-low, paratelic-high)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: combined low (telic-low, paratelic-high)
Number of subjects: 28
Study: 8336912

Group type: EXPERIMENTAL
Intervention: Dynamic retinoscopy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Subjective push-up method
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dynamic retinoscopy by four other examiners
Number of subjects: 57
Study: 2873176

Group type: EXPERIMENTAL
Intervention: Wearing multi-layer operating room masks during visits to patient rooms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not wearing masks)
Number of subjects: 0
Study: 29097499

Group type: EXPERIMENTAL
Intervention: Continuous high-dose lenalidomide (n=15)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Sequential azacitidine and lenalidomide (n=39)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Azacitidine only (n=34)
Number of subjects: 88
Study: 27655756

Group type: EXPERIMENTAL
Intervention: High egg (HE) - 150 g cooked egg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low egg (LE) - 75 g cooked egg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON) - no egg
Number of subjects: 16
Study: 24112439

Group type: EXPERIMENTAL
Intervention: Successful reaching action
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Unsuccessful reaching action
Number of subjects: 3
Study: 22430266

Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo‐oophorectomy (RRSO)
Number of subjects: 964

Group type: EXPERIMENTAL
Intervention: 6174delT mutation
Number of subjects: 964

Group type: COMPARATOR
Intervention: RRSO
Number of subjects: 964
Study: 20799930

Group type: EXPERIMENTAL
Intervention: Group Art Therapy plus standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control 'activity' group plus standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study: 18263672

Group type: EXPERIMENTAL
Intervention: dexmethylphenidate hydrochloride (d‐MPH)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 15719193

Group type: EXPERIMENTAL
Intervention: Side-to-side stapled anastomosis
Number of subjects: 122

Group type: COMPARATOR
Intervention: Handsewn end-to-end anastomosis
Number of subjects: 122
Study: 12480610

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg twice a day plus montelukast 10 mg at night for 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 microg twice a day
Number of subjects: 28
Study: 10585054

Group type: EXPERIMENTAL
Intervention: Nonheparin‐bonded circuit with no albumin preprime
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nonheparin‐bonded circuit with albumin preprime
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Heparin‐bonded circuit with no albumin preprime
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Heparin‐bonded circuit with albumin preprime
Number of subjects: 200
Study: 8933763

Group type: EXPERIMENTAL
Intervention: Cryotherapy in one eye
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Control eyes (no cryotherapy)
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Natural History cohort (no specific intervention)
Number of subjects: 1242
Study: 1910228

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin (2.4 million units) and procaine penicillin (2.0 million units) intramuscularly
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin and procaine penicillin for wounds repaired nine or more hours after injury
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group for wounds repaired nine or more hours after injury
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin and procaine penicillin for wounds involving the head or repaired within nine hours
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group for wounds involving the head or repaired within nine hours
Number of subjects: 320
Study: 7221401

Group type: EXPERIMENTAL
Intervention: Immediate provision of bath aids and instruction by a peripatetic occupational therapist
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual channels for receiving bath aids
Number of subjects: 100
Study: 30759035

Group type: EXPERIMENTAL
Intervention: Aspirin 20 mg BD (12-hourly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aspirin 75 mg OD (once-daily)
Number of subjects: 20
Study: 29291771

Group type: EXPERIMENTAL
Intervention: Enterococcus faecium strain SF68 (SF68)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate
Number of subjects: 27
Study: 28011811

Group type: EXPERIMENTAL
Intervention: safetxt intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control text messages
Number of subjects: 200
Study: 25071063

Group type: EXPERIMENTAL
Intervention: Accupedo‐Pro Pedometer app
Number of subjects: 12
Study: 21487115

Group type: EXPERIMENTAL
Intervention: First-person perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-person perspective
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-change
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perspective shifting
Number of subjects: 0
Study: 18642636

Group type: EXPERIMENTAL
Intervention: Median Nerve Stimulation (MNS) therapy
Number of subjects: 12
Study: 16564860

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Number of subjects: 247
Study: 13679496

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks (Group A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily for 8 weeks (Group B)
Number of subjects: 21
Study: 10735395

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg twice per day for 7 days (n = 128)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole, 160/800 mg twice per day for 14 days (n = 127)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 255

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 255
Study: 8827132

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1420504

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LDAC) 10 mg/m2 subcutaneously BID
Number of subjects: 141

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 141
Study: 3880775

Group type: EXPERIMENTAL
Intervention: High phenylalanine intake (900-4000 microM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low phenylalanine intake
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High phenylalanine intake
Number of subjects: 10
Study: 30837258

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PENTOCLO (PENtoxifylline+TOcopherol±CLOdronate)
Number of subjects: 16
Study: 28145050

Group type: COMPARATOR
Intervention: CYP2B6 516 G/G genotype
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: CYP2B6 516 T allele carriers
Number of subjects: 191
Study: 25946280

Group type: COMPARATOR
Intervention: Pulmonary-vein isolation alone
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Pulmonary-vein isolation plus ablation of complex fractionated electrograms
Number of subjects: 589

Group type: EXPERIMENTAL
Intervention: Pulmonary-vein isolation plus linear ablation
Number of subjects: 589
Study: 23475377

Group type: EXPERIMENTAL
Intervention: Assisting force (AF) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repelling force (RF) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CT) group
Number of subjects: 0
Study: 21494105

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subclavian vein cannulation
Number of subjects: 463

Group type: COMPARATOR
Intervention: Landmark method
Number of subjects: 463
Study: 19609105

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a low dose (3 microg/kg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a conventional dose (6 microg/kg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at both doses
Number of subjects: 86
Study: 16505299

Group type: EXPERIMENTAL
Intervention: Body weight support on a treadmill (BWSTT)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Defined over-ground mobility therapy (CONT)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Body weight support on a treadmill (BWSTT) and Defined over-ground mobility therapy (CONT)
Number of subjects: 146
Study: 12620436

Group type: COMPARATOR
Intervention: Transdermal estrogen therapy (newly initiated estrogen patch)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous transdermal estrogen therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 40
Study: 10710064

Group type: EXPERIMENTAL
Intervention: Ferumoxil (900 ml)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Double-contrast MRI (ferumoxil and gadolinium)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (5 controls for each intervention)
Number of subjects: 28
Study: 9093935

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP) 400 micrograms/day for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP) 800 micrograms/day for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral prednisone, 1 mg/kg/day for 2 weeks
Number of subjects: 0
Study: 1540019

Group type: EXPERIMENTAL
Intervention: Cod liver oil (10 ml daily)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Olive oil placebo (10 ml daily)
Number of subjects: 86
Study: 3457524

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg four times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aspirin (650 mg four times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30111466

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Heated humidified high flow nasal cannula (HHHFNC)
Number of subjects: 89
Study: 27710100

Group type: EXPERIMENTAL
Intervention: UV ink tattoos
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional dark ink tattoos
Number of subjects: 46
Study: 24885324

Group type: EXPERIMENTAL
Intervention: Yi Shen Jian Gu granules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22257943

Group type: EXPERIMENTAL
Intervention: Maitland's passive accessory mobilization
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 28
Study: 19995932

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 51
Study: 18625629

Group type: EXPERIMENTAL
Intervention: COBRA treatment comprising sulfasalazine, methotrexate and high‐dose step‐down prednisolone, intensified by adding hydroxychloroquine and continued low‐dose prednisolone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Monitoring group for CTX‐II
Number of subjects: 21